Rapid developments in colorectal cancer research have prompted the inclusion of molecular factors, such as MSI status and mutations in KRAS and BRAF, as important features for guiding cancer treatment in stage II–IV patients in the most recent edition of the AJCC (American Joint Committee on Cancer) Cancer Staging Manual15. Here, KRAS is linked to colorectal cancer.